C-rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells

Journal of Biological Chemistry

Volumn 289, Issue 46, 2014, Pages 31693-31707

  Neo, Wen Hao ^a   Lim, Jun Feng ^a   Grumont, Raelene ^b   Gerondakis, Steve ^b   Su, I Hsin ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL DEATH; DRUG THERAPY; TRANSCRIPTION;

CHROMATIN STRUCTURE; EMBRYONIC DEVELOPMENT; GROWTH INHIBITION; HISTONE METHYLTRANSFERASE; LYMPHOCYTE ACTIVATION; NUCLEAR TRANSLOCATIONS; POLYCOMB GROUP PROTEINS; TRANSCRIPTIONAL NETWORKS;

T-CELLS;

MESSENGER RNA; PENTOXIFYLLINE; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR REL; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; GSK126; INDOLE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ELECTROPORATION; EZH2 GENE; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRON; JURKAT CELL LINE; LEUKEMIA CELL LINE; LYMPHOID CELL; MOUSE; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL NUCLEUS; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEK293 CELL LINE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INDOLES; JURKAT CELLS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS; PENTOXIFYLLINE; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS C-REL; PYRIDONES; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84911440535     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.574517     Document Type: Article

References (60)

1. Lewis, E. B. (1978) A gene complex controlling segmentation in Drosophila. Nature 276, 565-570
2. Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., and Pirrotta, V. (2002) Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites. Cell 111, 185-196
3. Francis, N. J., Saurin, A. J., Shao, Z., and Kingston, R. E. (2001) Reconstitution of a functional core polycomb repressive complex. Mol. Cell 8, 545-556
4. Klymenko, T., Papp, B., Fischle, W., Köcher, T., Schelder, M., Fritsch, C., Wild, B., Wilm, M., and Müller, J. (2006) A polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysinebinding activities. Genes Dev. 20, 1110-1122
5. Müller, J., Hart, C. M., Francis, N. J., Vargas, M. L., Sengupta, A., Wild, B., Miller, E. L., O'Connor, M. B., Kingston, R. E., and Simon, J. A. (2002) Histone methyltransferase activity of a Drosophila polycomb group repressor complex. Cell 111, 197-208
6. Erhardt, S., Su, I. H., Schneider, R., Barton, S., Bannister, A. J., PerezBurgos, L., Jenuwein, T., Kouzarides, T., Tarakhovsky, A., and Surani, M. A. (2003) Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development. Development 130, 4235-4248
7. Wang, L., Jin, Q., Lee, J. E., Su, I. H., and Ge, K. (2010) Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc. Natl. Acad. Sci. U.S.A. 107, 7317-7322
8. Herz, H. M., and Shilatifard, A. (2010) The JARID2-PRC2 duality. Genes Dev. 24, 857-861
9. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., and Zhang, Y. (2002) Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298, 1039-1043
10. Sarma, K., Margueron, R., Ivanov, A., Pirrotta, V., and Reinberg, D. (2008) Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol. Cell. Biol. 28, 2718-2731
11. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893-2905
12. Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I. H., Hannon, G., Tarakhovsky, A., and Fuchs, E. (2009) Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136, 1122-1135
13. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G., Otte, A. P., Rubin, M. A., and Chinnaiyan, A. M. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629
14. Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G., Otte, A. P., Hayes, D. F., Sabel, M. S., Livant, D., Weiss, S. J., Rubin, M. A., and Chinnaiyan, A. M. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 100, 11606-11611
15. Matsukawa, Y., Semba, S., Kato, H., Ito, A., Yanagihara, K., and Yokozaki, H. (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97, 484-491
16. Su, I.-H., Basavaraj, A., Krutchinsky, A. N., Hobert, O., Ullrich, A., Chait, B. T., and Tarakhovsky, A. (2003) Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124-131
17. Su, I.-H., Dobenecker, M. W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., Viale, A., Reinberg, D., Wülfing, C., and Tarakhovsky, A. (2005) Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121, 425-436
18. Gaganova, M., Carrisi, C., Varano, G., Mainoldi, F., Z an ar di, F., Germain, P.-L., George, L., Alberghini, F., Ferrarini, L., Talukder, A. K., Ponzoni, M., Testa, G., Nojima, T., Doglioni, C., Kitamura, D., Toellner, K.-M., Su, I.-H., and Casola, S. (2013) Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest. 123, 5009-5022
19. Béguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang S. N., Wang, L., Ezponda, T., Martinez-Garcia, E., Zhang, H., Zheng, Y., Verma, S. K., McCabe, M. T., Ott, H. M., Van Aller, G. S., Kruger, R. G., Liu, Y., McHugh, C. F., Scott, D. W., Chung, Y. R., Kelleher, N., Shaknovich, R., Creasy, C. L., Gascoyne, R. D., Wong, K.-K., Cerchietti, L., Levine, R. L., Abdel-Wahab, O., Licht, J. D., Elemento, O., and Melnick, A. M. (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692
20. Attwooll, C., Oddi, S., Cartwright, P., Prospering E., Agger, K., Steensgaard, P., Wagener, C., Sardet, C., Moroni, M. C., and Helin, K. (2005) A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J. Biol. Chem. 280, 1199-1208
21. Bracken, A. P., Pasini, D., Capra, M., Prospering E., Colli, E., and Helin, K. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335
22. Visser, H. P., Gunster, M. J., Kluin-Nelemans, H. C., Manders, E. M., Raaphorst, F. M., Meijer, C. J., Willemze, R., and Otte, A. P. (2001) The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112, 950-958
23. Hwang, C., Giri, V. N., Wilkinson, J. C., Wright, C. W., Wilkinson, A. S., Cooney, K. A., and Duckett, C. S. (2008) EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Res. Treat. 107, 235-242
24. Chang, C. J., Yang, J. Y., Xia, W., Chen, C. T., Xie, X., Chao, C. H., Wood-ward, W. A., Hsu, J. M., Hortobagyi, G. N., and Hung, M. C. (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-ß-catenin signaling. Cancer Cell 19, 86-100
25. Tang, X., Milyavsky, M., Shats, I., Erez, N., Goldfinger, N., and Rotter, V. (2004) Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23, 5759-5769
26. Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F., Möller, P., Stilgenbauer, S., Pollack, J. R., and Wirth, T. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR- 26a. Blood 112, 4202-4212
27. Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., and Ochiai, A. (2011) MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30, 4118-4128
28. Nevins, J. R. (2001) The Rb/E2F pathway and cancer.Hum. Mol. Genet. 10, 699-703
29. Neri, F., Zippo, A., Krepelova, A., Cherubini, A., Rocchigiani, M., and Olivi ero, S. (2012) Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol. Cell. Biol. 32, 840-851
30. Königen, F., Grumont, R. J., Strasser, A., Metcalf, D., Li, R., Tarlinton, D., and Gerondakis, S. (1995) Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 9, 1965-1977
31. Szymczak, A. L., and Vignali, D. A. (2005) Development of 2A peptidebased strategies in the design of multicistronic vectors. Expert. Opin. Biol. Ther. 5, 627-638
32. van Galen, J. C., Dukers, D. F., Giroth, C., Sewalt, R. G., Otte, A. P., Meijer, C. J., and Raaphorst, F. M. (2004) Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur. J Immunol. 34, 1870-1881
33. Woolfe, A., Goodson, M., Goode, D. K., Snell, P., McEwen, G. K., Vavouri, T., Smith, S. F., North, P., Callaway, H., and Kelly, K. (2005) Highly conserved non-coding sequences are associated with vertebrate development. PLoS Biol. 3, e7
34. Loots, G. G., Locksley, R. M., Blankespoor, C. M., Wang, Z. E., Miller, W., Rubin, E. M., and Frazer, K. A. (2000) Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288, 136-140
35. Frazer, K. A., Pachter, L., Poliakov, A., Rubin, E. M., and Dubchak, I. (2004) VISTA: computational tools for comparative genomics. Nucleic Acids Res. 32, W273-W279
36. Furger, A., O'Sullivan, J. M., Binnie, A., Lee, B. A., and Proudfoot, N. J. (2002) Promoter proximal splice sites enhance transcription. Genes Dev. 16, 2792-2799
37. Heinemeyer, T., Wingender, E., Reuter, I., Hermjakob, H., Kel, A. E., Kel, O. V., Ignatieva, E. V., Ananko, E. A., Podkolodnaya, O. A., and Kolpakov, F. A. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res. 26, 362-367
38. Loots, G. G., and Ovcharenko, I. (2004) rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res. 32, W217-W221
39. Harris, J., Obère, S., Sharma, S., Sun, Q., Lin, R., Hiscott, J., and Grandvaux, N. (2006) Nuclear Accumulation of cRel following C-Terminal phosphorylation by TBK1/IKK ε. J. Immunol. 177, 2527-2535
40. May, M. J., and Ghosh, S. (1998) Signal transduction through NF-KB. Immunology Today 19, 80-88
41. Molitor, J. A., Walker, W. H., Doerre, S., Ballard, D.W., and Greene, W. C. (1990) NF-κB: a family of inducible and differentially expressed enhancerbinding proteins in human T cells. Proc. Natl. Acad. Sci. 87, 10028-10032
42. Garbati, M. R., Thompson, R. C., Haery, L., and Gilmore, T. D. (2011) A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett. 302, 76-83
43. Bunting, K., Rao, S., Hardy, K., Woltring, D., Denyer, G. S., Wang, J., Gerondakis, S., and Shannon, M. F. (2007) Genome-wide analysis of gene expression in T cells to identify targets of the NF-kappa B transcription factor c-Rel. J. Immunol. 178, 7097-7109
44. Wang, W., Tam, W. F., Hughes, C. C., Rath, S., and Sen, R. (1997) c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6, 165-174
45. Zabel, P., Schade, F. U., and Schlaak, M. (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187, 447-463
46. Shan, D., Wu, H. M., Yuan, Q. Y., Li, J., Zhou, R. L., and Liu, G. J. (2012) Pentoxifylline for diabetic kidney disease. Cochrane Database Syst. Rev. 2, CD006800
47. Albersen, M., Fandel, T. M., Zhang, H., Banie, L., Lin, G., De Ridder, D., Lin, C. S., and Lue, T. F. (2011) Pentoxifylline promotes recovery of erec- tile function in a rat model of postprostatectomy erectile dysfunction. Eur. Urol. 59, 286-296
48. McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., Della Pietra, A., 3rd, Diaz, E., LaFrance, L. V., Mellinger, M., Duquenne, C., Tian, X., Kruger, R. G., McHugh, C. F., Brandt, M., Miller, W. H., Dhanak, D., Verma, S. K., Tummino, P. J., and Creasy, C. L. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112
49. Chen, F. E., and Ghosh, G. (1999) Regulation of DNA binding by Rel/ NF-κB transcription factors: structural views. Oncogene 18, 6845-6852
50. Huang, D. B., Chen, Y. Q., Ruetsche, M., Phelps, C. B., and Ghosh, G. (2001) X-ray crystal structure of proto-oncogene product c-Rel bound to the CD28 response element of IL-2. Structure 9, 669-678
51. Tumes, D. J., Onodera, A., Suzuki, A., Shinoda, K., Endo, Y., Iwamura, C., Hosokawa, H., Koseki, H., Tokoyoda, K., Suzuki, Y., Motohashi, S., and Nakayama, T. (2013) The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity 39, 819-832
52. Rayet, B., and Gélinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947
53. Gilmore, T. D., Kalaitzidis, D., Liang, M.-C., and Starczynowski, D. T. (2004) The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23, 2275-2286
54. -/- B cells. Oncogene 22, 8472-8486
55. Catz, S. D., and Johnson, J. L. (2001) Transcriptional regulation of bcl-2 by nuclear factor kB and its significance in prostate cancer. Oncogene 20, 7342-7351
56. Rayet, B., Fan, Y., and Gélinas, C. (2003) Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF - κB -r egul at ed cell death inhibitors important for v-Rel transforming activity. Mol. Cell. Biol. 23, 1520-1533
57. Lerma-Díaz, J. M., Hernández-Flores, G., Domínguez-Rodríguez, J. R., Ortíz-Lazareno, P. C., Gómez-Contreras, P., Cervantes-Munguía, R., Scott-Algara, D., Aguilar-Lemarroy, A., Jave-Suárez, L. F., and Bravo-Cuellar, A. (2006) In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline: Involvement of caspase cascades and IκBα phosphorylation. Immunol. Lett. 103, 149-158
58. Bravo-Cuellar, A., Hernández-Flores, G., Lerma-Diaz, J. M., Domínguez-Rodríguez, J. R., Jave-Suárez, L. F., De Célis-Carrillo, R., Aguilar-Lemarroy, A., Gómez-Lomeli, P., and Ortiz-Lazareno, P. C. (2013) Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation of p65. J. Biomed. Sci. 20, 13
59. Crooks, G. E., Hon, G., Chandonia, J.-M., and Brenner, S. E. (2004) We-bLogo: a sequence logo generator. Genome Res. 14, 1188-1190
60. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J., and Higgins, D. G. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948